XSpray Pharma AB (LTS:0GHZ) E10: kr-4.13 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0GHZ XSpray Pharma AB LTS:0GHZ
31 GF Score
Price kr15.14
! 1 Warning Sign
View Full Analysis

What is XSpray Pharma AB E10?

XSpray Pharma AB LTS:0GHZ 31 E10 is kr-4.13 as of Mar. 2026. GuruFocus rates LTS:0GHZ with a GF Score™ of 31/100. The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

XSpray Pharma AB's adjusted earnings per share data for the three months ended in Mar. 2026 was kr-0.850. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is kr-4.13 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-08-03), XSpray Pharma AB's current stock price is kr15.14. XSpray Pharma AB's E10 for the quarter that ended in Mar. 2026 was kr-4.13. XSpray Pharma AB's Shiller PE Ratio of today is .


XSpray Pharma AB  (LTS:0GHZ) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


XSpray Pharma AB E10 Related Terms


XSpray Pharma AB E10 Historical Data

* Premium members only.

The historical data trend for XSpray Pharma AB's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

XSpray Pharma AB E10 Chart

XSpray Pharma AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

XSpray Pharma AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -4.13

LTS:0GHZ vs VRTX, REGN, RVMD: E10 Comparison

For the Biotechnology subindustry, XSpray Pharma AB's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


XSpray Pharma AB Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, XSpray Pharma AB's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where XSpray Pharma AB's Shiller PE Ratio falls into.


LTS:0GHZ
31GF Score
XSpray Pharma AB LTS:0GHZ
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

XSpray Pharma AB E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, XSpray Pharma AB's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.85/133.5600*133.5600
=-0.850

Current CPI (Mar. 2026) = 133.5600.

XSpray Pharma AB Quarterly Data

per share eps CPI Adj_EPS
201512 0.000 100.276 0.000
201609 -0.989 101.138 -1.306
201612 0.740 102.022 0.969
201703 -0.935 102.022 -1.224
201706 0.103 102.752 0.134
201709 -0.402 103.279 -0.520
201712 -0.403 103.793 -0.519
201803 -0.112 103.962 -0.144
201806 -0.468 104.875 -0.596
201809 -0.281 105.679 -0.355
201812 -0.720 105.912 -0.908
201903 -0.477 105.886 -0.602
201906 -0.580 106.742 -0.726
201909 -0.580 107.214 -0.723
201912 -1.141 107.766 -1.414
202003 -0.589 106.563 -0.738
202006 -0.860 107.498 -1.069
202009 -0.645 107.635 -0.800
202012 -0.767 108.296 -0.946
202103 -0.683 108.360 -0.842
202106 -0.832 108.928 -1.020
202109 -0.683 110.338 -0.827
202112 -2.507 112.486 -2.977
202203 -0.860 114.825 -1.000
202206 -1.321 118.384 -1.490
202209 -1.312 122.296 -1.433
202212 -2.407 126.365 -2.544
202303 -1.454 127.042 -1.529
202306 -2.143 129.407 -2.212
202309 -1.501 130.224 -1.539
202312 -1.767 131.912 -1.789
202403 -2.073 132.205 -2.094
202406 -1.566 132.716 -1.576
202409 -2.373 132.304 -2.396
202412 -2.295 132.987 -2.305
202503 -1.089 132.825 -1.095
202506 -2.245 133.699 -2.243
202509 -1.216 133.480 -1.217
202512 -0.865 133.390 -0.866
202603 -0.850 133.560 -0.850

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of kr-4.13 mean?
XSpray Pharma AB (LTS:0GHZ) has a E10 of kr-4.13 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on XSpray Pharma AB and its competitors.
Is XSpray Pharma AB's E10 too high?
XSpray Pharma AB's current E10 is kr-4.13. Overall, XSpray Pharma AB has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does XSpray Pharma AB's E10 compare to VRTX and REGN?
XSpray Pharma AB's E10 of kr-4.13 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on XSpray Pharma AB and its competitors. XSpray Pharma AB's current E10 is kr-4.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is XSpray Pharma AB stock overvalued right now?
XSpray Pharma AB (LTS:0GHZ) has a current E10 of kr-4.13. The current E10 is kr-4.13. XSpray Pharma AB's overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For XSpray Pharma AB (LTS:0GHZ), the current E10 is kr-4.13 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

XSpray Pharma AB Business Description

Other Exchanges XSPRAY:Sweden6XP:Germany
Address Scheeles vag 2, Solna, SWE, SE-171 65
XSpray Pharma AB is a pharmaceutical company focused on developing improved PKIs for cancer treatment, leveraging its proprietary HyNap technology platform. The company aims to enhance clinical outcomes for cancer patients by improving the efficacy, safety, and patient experience of existing cancer therapies. Its product portfolio includes Dasynoc and other product candidates in different stages of development such as XS003 nilotinib, XS008 axitinib, and other.
31GF Score

Get the complete analysis for LTS:0GHZ

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr15.14
Price